Bio News

U.S.-based Tango Therapeutics said it will reduce its workforce by about 14%.
Tango Therapeutics reported an objective response rate of 82% with a combination of vopimetostat and Revolution Medicines’ RAS(ON) inhibitor.
Tango Therapeutics plans to begin a phase 3 trial in patients with metastatic pancreatic ductal adenocarcinoma in the first half of next year.

Biobook Team
biobookmedia@biobook.co.krEuropean CHMP Recommends Approval of AstraZeneca’s Blood Pressure Drug Baxpendi
Novo Seeks U.S. and European Approval for Sickle Cell Drug Etavopivat
Rezolute Meets Primary Endpoint in Phase 3 Trial for Tumor Hyperinsulinism; FDA Meeting Ahead
Five Brain Disease Startups Raise $450 Million in a Few Weeks
American Cancer Society Revises Prostate Cancer Screening Guidelines for First Time in 16 Years
Shin Dong-kook Raises Stake in Hanmi Science to 30.18% With Over-the-Counter Purchase of 1.38 Million Shares